Trevi Therapeutics, Inc.

NASDAQ:TRVI

4 (USD) • At close December 24, 2024
Bedrijfsnaam Trevi Therapeutics, Inc.
Symbool TRVI
Munteenheid USD
Prijs 4
Beurswaarde 357,462,800
Dividendpercentage 0%
52-weken bereik 1.27 - 4.675
Industrie Biotechnology
Sector Healthcare
CEO Ms. Jennifer L. Good
Website https://www.trevitherapeutics.com

An error occurred while fetching data.

Over Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with

Vergelijkbare Aandelen

Aptose Biosciences Inc. logo

Aptose Biosciences Inc.

APTO

0.25 USD

iCAD, Inc. logo

iCAD, Inc.

ICAD

1.78 USD

Axcella Health Inc. logo

Axcella Health Inc.

AXLA

4.58 USD

DURECT Corporation logo

DURECT Corporation

DRRX

0.97 USD

Ardelyx, Inc. logo

Ardelyx, Inc.

ARDX

4.64 USD

Aeglea BioTherapeutics, Inc. logo

Aeglea BioTherapeutics, Inc.

AGLE

12.01 USD

LAVA Therapeutics N.V. logo

LAVA Therapeutics N.V.

LVTX

0.975 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)